Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

Longeveron Inc. (NASDAQ: LGVN) is set to report its full-year financial results for 2025 and provide a business update on March 17, 2026, after the close of U.S. financial markets. The Miami-based clinical stage biotechnology company focuses on developing cellular therapies aimed at treating life-threatening, rare pediatric conditions and chronic aging-related issues. Following the results announcement, Longeveron will host a conference call and webcast at 4:30 p.m. ET on the same day, providing stakeholders with an opportunity to gain insights into the company’s performance and future directions. The conference call can be accessed by dialing 1.877.407.0789 with Conference ID: 13758462.

Longeveron’s flagship investigational product, laromestrocel (LOMECEL-B®), is an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors. This regenerative medicine has shown promise through its various mechanisms of action, which include enhancing vascularization, promoting regeneration, and providing anti-inflammatory effects—making it a candidate for multiple therapeutic applications. The company is actively developing laromestrocel across four indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM), and Aging-related Frailty.

The development programs for laromestrocel have garnered significant attention from the FDA, receiving five key designations: Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, alongside Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the Alzheimer’s program. For further details, stakeholders are encouraged to visit Longeveron’s website and follow the company’s updates on various social media platforms.

As Longeveron Inc. (NASDAQ: LGVN) prepares to report its 2025 full-year financial results on March 17, 2026, investors should closely monitor both the outcomes of this report and the accompanying conference call. Given the company's focus on developing cellular therapies for critical medical needs, particularly in pediatric and aging populations, the results are likely to provide insight into the current status and future trajectory of its product pipeline, specifically laromestrocel (LOMECEL-B®).

Investors should be particularly attentive to any updates regarding the ongoing clinical trials, especially those related to the four targeted indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), pediatric dilated cardiomyopathy (PDCM), and aging-related frailty. Positive developments in these areas, especially considering previous FDA designations such as Orphan Drug and Fast Track, could signal significant commercial value and bolster investor confidence.

Additionally, the market's reaction to financial results—such as revenue growth, R&D expenditures, and cash burn rates—will be pivotal in assessing the company’s operational health. A focus on financial sustainability in the face of extensive clinical trial investments may be a point of concern for investors. Monitoring the balance sheet and cash runway will be crucial, as Longeveron's continued ability to fund its operations and growth initiatives hinge on favorable financial metrics.

Overall, while Longeveron's innovative approaches to addressing unmet medical needs present substantial potential upside, investors should approach the upcoming results with caution, fostering a strategy of thorough due diligence and risk assessment. Splitting investments across various stages of clinical progress and potential market entries may provide a balanced way to capitalize on Longeveron's prospects while mitigating risk.